{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T22:24:48Z","timestamp":1792448688965,"version":"4.5.0"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T00:00:00Z","timestamp":1754611200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008021","name":"Bristol Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008021","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cutaneous lupus erythematosus (CLE) is a chronic inflammatory skin disease with various clinical subtypes. Although its pathogenesis is not yet fully understood, T-cell-mediated autoimmunity and elevated levels of type I interferons (IFNs) are two major factors that contribute to the development of cutaneous lesions. Type I IFNs transduce their signal via tyrosine kinase 2 (TYK2).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To investigate the impact of TYK2 signalling in preclinical models of CLE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>CLE skin biopsies were investigated by RNA sequencing (RNAseq) and immunohistochemistry. T cells isolated from CLE skin biopsies (lesional T cells) were restimulated with anti-CD3\/anti-CD28 and cytokine release was quantified by enzyme-linked immunosorbent assay and Luminex\u00ae. Primary human keratinocytes and three-dimensional skin models were stimulated with IFN-\u03b1 or lesional T-cell supernatant in the presence or absence of the TYK2 inhibitor deucravacitinib, followed by RNAseq. Skin biopsies from patients with different CLE subtypes were treated ex vivo with deucravacitinib followed by real-time quantitative polymerase chain reaction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Bulk RNAseq revealed a strong correlation between TYK2 and interface dermatitis, a histological hallmark of CLE. Immunohistochemistry confirmed a high abundance of TYK2 in different CLE subtypes. Inhibiting TYK2 reduced inflammation and normalized epidermal impairments in primary human keratinocytes, reconstructed human epidermis and CLE T cells. Ex vivo TYK2 inhibition in CLE skin biopsies reduced IFN response and necroptosis-related gene expression. Finally, four patients with different therapy-refractory subtypes of CLE (acute, subacute, chronic discoid, chilblain CLE) were successfully treated with deucravacitinib.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>IFN-\u03b1 and T-cell-derived cytokines both contribute to skin inflammation in CLE. TYK2 inhibition is a promising approach for different subtypes of CLE as it controls inflammation in various preclinical models and patients with CLE who are refractory to treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/bjd\/ljaf293","type":"journal-article","created":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T11:43:47Z","timestamp":1753357427000},"page":"1192-1203","source":"Crossref","is-referenced-by-count":13,"title":["Tyrosine kinase 2 inhibition improves clinical and molecular hallmarks in subtypes of cutaneous lupus"],"prefix":"10.1093","volume":"193","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-2797-6867","authenticated-orcid":false,"given":"Sophia","family":"Wasserer","sequence":"first","affiliation":[{"name":"Department of Dermatology and Allergy, Klinikum rechts der Isar, Technical University of Munich , Munich ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6332-3323","authenticated-orcid":false,"given":"Peter","family":"Seiringer","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy, Klinikum rechts der Isar, Technical University of Munich , Munich ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7939-3983","authenticated-orcid":false,"given":"Nils","family":"Kurzen","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy, Klinikum rechts der Isar, Technical University of Munich , Munich ,","place":["Germany"]},{"name":"Department of Dermatology and Allergy, University Hospital, Ludwig-Maximilians-University (LMU) Munich , Munich ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6051-4036","authenticated-orcid":false,"given":"Manja","family":"Jargosch","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy, Klinikum rechts der Isar, Technical University of Munich , Munich ,","place":["Germany"]},{"name":"Center of Allergy and Environment (ZAUM), Technical University of Munich and Helmholtz Center Munich ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1363-6247","authenticated-orcid":false,"given":"Jessica","family":"Eigemann","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy, Klinikum rechts der Isar, Technical University of Munich , Munich ,","place":["Germany"]},{"name":"Center of Allergy and Environment (ZAUM), Technical University of Munich and Helmholtz Center Munich ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9196-5456","authenticated-orcid":false,"given":"G\u00f6rkem","family":"Aydin","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy, Klinikum rechts der Isar, Technical University of Munich , Munich ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4385-2193","authenticated-orcid":false,"given":"Theresa","family":"Raunegger","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy, Klinikum rechts der Isar, Technical University of Munich , Munich ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3203-8084","authenticated-orcid":false,"given":"Carsten B","family":"Schmidt-Weber","sequence":"additional","affiliation":[{"name":"Center of Allergy and Environment (ZAUM), Technical University of Munich and Helmholtz Center Munich ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1166-2355","authenticated-orcid":false,"given":"Stefanie","family":"Eyerich","sequence":"additional","affiliation":[{"name":"Center of Allergy and Environment (ZAUM), Technical University of Munich and Helmholtz Center Munich ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5352-5105","authenticated-orcid":false,"given":"Tilo","family":"Biedermann","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy, Klinikum rechts der Isar, Technical University of Munich , Munich ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0094-2674","authenticated-orcid":false,"given":"Kilian","family":"Eyerich","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy, University Hospital, Albert-Ludwigs-University Freiburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1992-2836","authenticated-orcid":false,"given":"Felix","family":"Lauffer","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy, University Hospital, Ludwig-Maximilians-University (LMU) Munich , Munich ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,8,8]]},"reference":[{"key":"2025111813172756200_ljaf293-B1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ejim.2023.02.004","article-title":"Mortality and causes of death in systemic lupus erythematosus over the last decade: data from a large population-based study","volume":"112","author":"Zen","year":"2023","journal-title":"Eur J Intern Med"},{"key":"2025111813172756200_ljaf293-B2","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.jaad.2010.02.008","article-title":"Quality of life in cutaneous lupus erythematosus","volume":"64","author":"Klein","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"2025111813172756200_ljaf293-B3","doi-asserted-by":"crossref","first-page":"984229","DOI":"10.3389\/fmed.2022.984229","article-title":"Clinical aspects of cutaneous lupus erythematosus","volume":"9","author":"Elmgren","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"2025111813172756200_ljaf293-B4","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1080\/1744666X.2020.1805316","article-title":"New insights into the progression from cutaneous lupus to systemic lupus erythematosus","volume":"16","author":"Zhou","year":"2020","journal-title":"Expert Rev Clin Immunol"},{"key":"2025111813172756200_ljaf293-B5","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1038\/jid.2008.96","article-title":"An IFN-associated cytotoxic cellular immune response against viral, self-, or tumor antigens is a common pathogenetic feature in \u201cinterface dermatitis\u201d","volume":"128","author":"Wenzel","year":"2008","journal-title":"J Invest Dermatol"},{"key":"2025111813172756200_ljaf293-B6","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1111\/j.1365-2133.2005.06784.x","article-title":"Scarring skin lesions of discoid lupus erythematosus are characterized by high numbers of skin-homing cytotoxic lymphocytes associated with strong expression of the type I interferon-induced protein MxA","volume":"153","author":"Wenzel","year":"2005","journal-title":"Br J Dermatol"},{"key":"2025111813172756200_ljaf293-B7","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.autrev.2004.10.003","article-title":"Subacute cutaneous lupus erythematosus: 25-year evolution of a prototypic subset (subphenotype) of lupus erythematosus defined by characteristic cutaneous, pathological, immunological, and genetic findings","volume":"4","author":"Sontheimer","year":"2005","journal-title":"Autoimmun Rev"},{"key":"2025111813172756200_ljaf293-B8","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.autrev.2017.05.009","article-title":"Pathogenesis of cutaneous lupus erythema associated with and without systemic lupus erythema","volume":"16","author":"Zhang","year":"2017","journal-title":"Autoimmun Rev"},{"key":"2025111813172756200_ljaf293-B9","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/s41584-019-0272-0","article-title":"Cutaneous lupus erythematosus: new insights into pathogenesis and therapeutic strategies","volume":"15","author":"Wenzel","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"2025111813172756200_ljaf293-B10","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1038\/jid.2012.207","article-title":"IgG and IgM autoantibody differences in discoid and systemic lupus patients","volume":"132","author":"Chong","year":"2012","journal-title":"J Invest Dermatol"},{"key":"2025111813172756200_ljaf293-B11","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1016\/j.jid.2018.02.034","article-title":"Type I immune response induces keratinocyte necroptosis and is associated with interface dermatitis","volume":"138","author":"Lauffer","year":"2018","journal-title":"J Invest Dermatol"},{"key":"2025111813172756200_ljaf293-B12","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/jdv.14673","article-title":"Immune response patterns in non-communicable inflammatory skin diseases","volume":"32","author":"Eyerich","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025111813172756200_ljaf293-B13","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1111\/exd.14146","article-title":"Cutaneous lupus erythematosus: the impact of self-amplifying innate and adaptive immune responses and future prospects of targeted therapies","volume":"29","author":"Fetter","year":"2020","journal-title":"Exp Dermatol"},{"key":"2025111813172756200_ljaf293-B14","first-page":"426","article-title":"Lupus erythematodes","volume":"21","author":"G\u00fcnther","year":"2023","journal-title":"J Dtsch Dermatol Ges"},{"key":"2025111813172756200_ljaf293-B15","doi-asserted-by":"crossref","first-page":"e689","DOI":"10.1016\/S2665-9913(21)00291-5","article-title":"FDA approval for anifrolumab in patients with lupus","volume":"3","author":"Burki","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"2025111813172756200_ljaf293-B16","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/s41584-023-00948-y","article-title":"Precision medicine in systemic lupus erythematosus","volume":"19","author":"Fasano","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"2025111813172756200_ljaf293-B17","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of anifrolumab in active systemic lupus erythematosus","volume":"382","author":"Morand","year":"2020","journal-title":"N Engl J Med"},{"key":"2025111813172756200_ljaf293-B18","doi-asserted-by":"crossref","first-page":"e000284","DOI":"10.1136\/lupus-2018-000284","article-title":"Anifrolumab effects on rash and arthritis: impact of the type I interferon gene signature in the phase IIb MUSE study in patients with systemic lupus erythematosus","volume":"5","author":"Merrill","year":"2018","journal-title":"Lupus Sci Med"},{"key":"2025111813172756200_ljaf293-B19","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/art.39962","article-title":"Anifrolumab, an anti-interferon-\u03b1 receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus","volume":"69","author":"Furie","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2025111813172756200_ljaf293-B20","doi-asserted-by":"crossref","first-page":"e000819","DOI":"10.1136\/lupus-2022-000819","article-title":"Panoramic view of clinical features of lupus erythematosus: a cross-sectional multicentre study from China","volume":"10","author":"Jin","year":"2023","journal-title":"Lupus Sci Med"},{"key":"2025111813172756200_ljaf293-B21"},{"key":"2025111813172756200_ljaf293-B22","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/cts.13435","article-title":"First-in-human study of deucravacitinib: a selective, potent, allosteric small-molecule inhibitor of tyrosine kinase 2","volume":"16","author":"Catlett","year":"2023","journal-title":"Clin Transl Sci"},{"key":"2025111813172756200_ljaf293-B23","doi-asserted-by":"crossref","first-page":"eaaw1736","DOI":"10.1126\/scitranslmed.aaw1736","article-title":"Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain","volume":"11","author":"Burke","year":"2019","journal-title":"Sci Transl Med"},{"key":"2025111813172756200_ljaf293-B24","doi-asserted-by":"crossref","first-page":"8973","DOI":"10.1021\/acs.jmedchem.9b00444","article-title":"Highly selective inhibition of tyrosine kinase 2 (TYK2) for the treatment of autoimmune diseases: discovery of the allosteric inhibitor BMS-986165","volume":"62","author":"Wrobleski","year":"2019","journal-title":"J Med Chem"},{"key":"2025111813172756200_ljaf293-B25","doi-asserted-by":"crossref","first-page":"154605","DOI":"10.1016\/j.cyto.2018.11.022","article-title":"The influence of interferon on healthy and diseased skin","volume":"132","author":"Hile","year":"2020","journal-title":"Cytokine"},{"key":"2025111813172756200_ljaf293-B26","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jaad.2022.07.002","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial","volume":"88","author":"Armstrong","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"2025111813172756200_ljaf293-B27","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1136\/annrheumdis-2022-eular.5020a","article-title":"LB0004 Efficacy and safety of deucravacitinib, an oral allosteric TYK2 inhibitor, in patients with active systemic lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study","volume":"81","author":"Morand","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2025111813172756200_ljaf293-B28","author":"ClinicalTrials.gov"},{"key":"2025111813172756200_ljaf293-B29","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/jid.1968.15","article-title":"Suction blister device for separation of viable epidermis from dermis","volume":"50","author":"Kiistala","year":"1968","journal-title":"J Invest Dermatol"},{"key":"2025111813172756200_ljaf293-B30","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025111813172756200_ljaf293-B31","first-page":"291","article-title":"Quantification of histochemical staining by colour deconvolution","volume":"23","author":"Ruifrok","year":"2001","journal-title":"Anal Quant Cytol Histol"},{"key":"2025111813172756200_ljaf293-B32","article-title":"Integration of phenomics and transcriptomics data to reveal drivers of inflammatory processes in the skin","author":"Batra","year":"2020","journal-title":"bioRxiv"},{"key":"2025111813172756200_ljaf293-B33","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.rdc.2009.12.008","article-title":"Interferon-alpha: a therapeutic target in systemic lupus erythematosus","volume":"36","author":"Crow","year":"2010","journal-title":"Rheum Dis Clin North Am"},{"key":"2025111813172756200_ljaf293-B34","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1080\/08916930310001625952","article-title":"Microarray analysis of interferon-regulated genes in SLE","volume":"36","author":"Crow","year":"2003","journal-title":"Autoimmunity"},{"key":"2025111813172756200_ljaf293-B35","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41586-022-04642-z","article-title":"TLR7 gain-of-function genetic variation causes human lupus","volume":"605","author":"Brown","year":"2022","journal-title":"Nature"},{"key":"2025111813172756200_ljaf293-B36","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nri3787","article-title":"Type I interferons in infectious disease","volume":"15","author":"McNab","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"2025111813172756200_ljaf293-B37","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.yexcr.2010.12.017","article-title":"CXCR3 in T cell function","volume":"317","author":"Groom","year":"2011","journal-title":"Exp Cell Res"},{"key":"2025111813172756200_ljaf293-B38","doi-asserted-by":"crossref","first-page":"eabn2263","DOI":"10.1126\/scitranslmed.abn2263","article-title":"Nonlesional lupus skin contributes to inflammatory education of myeloid cells and primes for cutaneous inflammation","volume":"14","author":"Billi","year":"2022","journal-title":"Sci Transl Med"},{"key":"2025111813172756200_ljaf293-B39","doi-asserted-by":"crossref","first-page":"S202","DOI":"10.1016\/j.jaci.2006.12.162","article-title":"Overexpression of interleukin 13 (IL-13) in the skin induces dermatitis and pulmonary inflammation and airway hyperresponsiveness to allergen challenge","volume":"119","author":"Zheng","year":"2007","journal-title":"J Allergy Clin Immunol"},{"key":"2025111813172756200_ljaf293-B40","doi-asserted-by":"crossref","first-page":"3695","DOI":"10.4049\/jimmunol.174.6.3695","article-title":"IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes","volume":"174","author":"Boniface","year":"2005","journal-title":"J Immunol"},{"key":"2025111813172756200_ljaf293-B41","volume-title":"Histopathologie der Haut. 2. Auflage, \u00fcberarbeitet und erweitert","author":"Cerroni","year":"2016"},{"key":"2025111813172756200_ljaf293-B42","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.bcp.2012.11.004","article-title":"IFN\u03b1 converts IL-22 into a cytokine efficiently activating STAT1 and its downstream targets","volume":"85","author":"Bachmann","year":"2013","journal-title":"Biochem Pharmacol"},{"key":"2025111813172756200_ljaf293-B43","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/S0140-6736(18)32167-6","article-title":"Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study","volume":"392","author":"van Vollenhoven","year":"2018","journal-title":"Lancet"},{"key":"2025111813172756200_ljaf293-B44","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1136\/ard-2022-222858","article-title":"Phase 3, multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosus","volume":"81","author":"van Vollenhoven","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2025111813172756200_ljaf293-B45","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1002\/acr.25058","article-title":"Improvement in cutaneous lupus erythematosus after twenty weeks of belimumab use: a systematic review and meta-analysis","volume":"75","author":"Kneeland","year":"2023","journal-title":"Arthritis Care Res"},{"key":"2025111813172756200_ljaf293-B46","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/art.42391","article-title":"Deucravacitinib, a tyrosine kinase 2 inhibitor, in systemic lupus erythematosus: a phase II, randomized, double-blind, placebo-controlled trial","volume":"75","author":"Morand","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"2025111813172756200_ljaf293-B47","doi-asserted-by":"crossref","first-page":"e434","DOI":"10.1111\/jdv.19667","article-title":"Rapid clinical improvement of refractory subacute cutaneous lupus erythematosus with oral tyrosine kinase 2 inhibitor deucravacitinib: a case report","volume":"38","author":"Kurz","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025111813172756200_ljaf293-B48","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jdcr.2023.07.030","article-title":"Successful treatment of refractory subacute cutaneous lupus erythematosus with deucravacitinib","volume":"39","author":"Bouch\u00e9","year":"2023","journal-title":"JAAD Case Rep"},{"key":"2025111813172756200_ljaf293-B49","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jdcr.2024.04.032","article-title":"Discoid lupus erythematosus successfully treated with deucravacitinib","volume":"49","author":"Ezeh","year":"2024","journal-title":"JAAD Case Rep"},{"key":"2025111813172756200_ljaf293-B50","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jdcr.2023.11.029","article-title":"Treatment of recalcitrant lupus erythematosus tumidus with deucravacitinib","volume":"45","author":"Zhang","year":"2024","journal-title":"JAAD Case Rep"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljaf293\/63981136\/ljaf293.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/193\/6\/1192\/63981136\/ljaf293.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/193\/6\/1192\/63981136\/ljaf293.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T18:17:43Z","timestamp":1763489863000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/193\/6\/1192\/8226261"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,8]]},"references-count":50,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,8,8]]},"published-print":{"date-parts":[[2025,11,18]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljaf293","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,8,8]]}}}